

AlphaRx's Topical Indaflex™ Demonstrates Significant Localized Anti-inflammatory Activity Against Oral NSAIDs (Non-steroidal Anti-inflammatory Drug) In Preclinical Study

Markham, June 9 /CNW/ AlphaRx Inc. (OTCBB: ALRX) is pleased to announce recently compiled data and results on its lead pharmaceutical product Indaflex™, a topical Indomethacin formulation incorporated in the Company's drug delivery system.

Anti-inflammatory activity was investigated in the laboratory using a Carrageenan non-infective inflammation model to compare the effectiveness of topical Indaflex™ to oral Rofecoxib (Vioxx™) suspension and oral Indomethacin suspension (10 mg/kg of Indomethacin vs. 5.0 mg/ml of Rofecoxib vs. 5.0 mg/ml Indomethacin). Inflammation reached peak levels after 4 hours with Indaflex™ providing approximately 80% suppression of inflammation by topical administration, compared to approximately 20% and 25% suppression by Rofecoxib and Indomethacin respectively by oral administration. The data demonstrated a significantly greater suppression of Carrageenan induced inflammation with topical Indaflex.

"We believe the localized anti-inflammatory activity of topical Indaflex™ is significantly higher than oral Rofecoxib and oral Indomethacin and may have less side effects associated with NSAIDs administered orally," stated President & CEO of AlphaRx Inc., Mr. Michael Lee.

Indomethacin is a well-known and FDA-approved Non-steroidal Anti-inflammatory Drug (NSAID) that relieves the inflammation and pain associated with rheumatoid arthritis (rheumatism), osteoarthritis, ankylosing spondylitis, and gout.

Vioxx™ is a prescription medicine called a COX-2 selective, Non-steroidal Anti-inflammatory Drug (NSAID). Vioxx™ is used in adults for the relief of the pain and inflammation (swelling and soreness) of osteoarthritis (arthritis from wear and tear on your bones and your joints)

NSAIDs are frequently associated with significant adverse gastrointestinal (GI) side effects such as stomach ulcers and internal bleeding in patients using these compounds. Steroidal drugs also seriously compromise the human immune system. These side effects are a major concern and limit or prohibit their use by many patients. The US market for non-steroidal anti-inflammatory drugs (NSAID) in 2002/2003 was estimated to be US\$12 billion.

About Indaflex(TM)

Indaflex is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to start clinical development soon for use in the treatment symptoms of arthritis. Arthritis is the most common chronic condition in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has long-standing and proven clinical treatment records. With AlphaRx's enhanced proprietary delivery system, the company believes its clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex delivery, the company hopes may circumvent the significant GI side-effects found with orally ingested NSAID's.

About AlphaRx Inc. <http://www.alpharx.com>

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. AlphaRx's broad product pipeline consists of drugs with a strong commercial potential that can be dramatically improved through the application of its proprietary BCD(TM) drug delivery technology. For more information, please visit <http://www.alpharx.com>

For more information, please contact:

Agora Investor Relations Corp., Web: <http://www.agoracom.com> (Select "AlphaRx" Forum), E-mail: ALRX@Agoracom.com

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.